Xceleron, a Germantown, Md.-based CRO that applies ultra-sensitive analytical technology to novel clinical designs, has formed a partnership with Crystal Pharmatech, a China-based technology-driven research CRO.
The companies will combine accelerator mass spectrometry (AMS) technology with the expertise to cost-effectively remove pharmacokinetic uncertainty by providing better early clinical and solid state information. This enables their customers to make better decisions sooner about a candidate’s later-stage readiness.
“At Xceleron, we believe that technology can get life-changing drugs to people who need them, sooner and at a lower cost. This partnership will help our clients do that by efficiently and cost-effectively answering critical questions earlier,” said Dr. Michael Butler, CEO of Xceleron.
Dr. Alex Chen, CEO of Crystal Pharmatech, added, “Having robust bioavailability and pharmacokinetic data at the outset provides a strong foundation for determining the best solid form and formulation. Each company brings significant expertise to the discussion of novel clinical outcomes.”